Universal Health Realty Income Trust (UHT) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
17 Jun, 2026Executive summary
Net income for Q4 2025 was $4.3 million ($0.31 per diluted share), down from $4.7 million ($0.34 per diluted share) in Q4 2024, mainly due to lower property income and a vacated medical office building in Texas.
Full-year 2025 net income was $17.6 million ($1.27 per diluted share), compared to $19.2 million ($1.39 per diluted share) in 2024, reflecting lower property income and a nonrecurring depreciation expense.
Funds from operations (FFO) for Q4 2025 was $11.74 million ($0.85 per diluted share), nearly flat year-over-year; full-year FFO was $47.7 million ($3.44 per diluted share), slightly down from $47.9 million ($3.46 per diluted share) in 2024.
Financial highlights
Lease revenue for Q4 2025 totaled $24.5 million, nearly unchanged from Q4 2024; full-year lease revenue was $99.2 million, also flat year-over-year.
Depreciation and amortization expense increased to $7.1 million in Q4 2025 and $28.9 million for the year, up from $6.8 million and $27.4 million, respectively.
Dividend per share for Q4 2025 was $0.745, with a total annual dividend of $2.96 per share.
Outlook and guidance
Construction began in February 2026 on a new 80,000 sq. ft. medical office building in Palm Beach Gardens, FL, expected to complete in Q4 2026 at a cost of $34 million.
A 10-year master lease for 75% of the new building's space has been executed, with potential for third-party leases to reduce this commitment.
Latest events from Universal Health Realty Income Trust
- Trustee elections, executive pay, and auditor ratification all passed with no shareholder questions.UHT
AGM 202622 Jun 2026 - Trustees, executive pay, and auditor were approved by shareholders in a virtual meeting.UHT
AGM 202522 Jun 2026 - All proposals, including trustee elections and auditor ratification, were approved by shareholders.UHT
AGM 202421 Jun 2026 - Q2 and H1 2024 net income and FFO rose, with higher dividends and ongoing industry risks.UHT
Q2 202417 Jun 2026 - Net income, revenues, and FFO rose, with higher interest costs and expanded credit capacity.UHT
Q3 202417 Jun 2026 - Net income and FFO rose year-over-year, supported by property income and prudent capital actions.UHT
Q4 202417 Jun 2026 - Raised 2025 guidance after strong Q2 results and incremental Medicaid reimbursements.UHT
Q2 202517 Jun 2026 - Mixed earnings and revenue trends, with stable liquidity but ongoing regulatory and litigation risks.UHT
Q1 202517 Jun 2026 - Net income and FFO rose, credit capacity expanded, and new medical office construction began.UHT
Q1 202617 Jun 2026